Off-label use of intravitreal bevacizumab: A global conundrum.

Authors :: Singh S
Saxena S
Akduman L
Meyer CH
Source :: Indian journal of ophthalmology [Indian J Ophthalmol] 2024 May 01; Vol. 72 (5), pp. 617-619. Date of Electronic Publication: 2024 Apr 22.
Publication Year :: 2024
Abstract: Bevacizumab is a monoclonal, humanized, full-length antibody targeting vascular endothelial growth factor(VEGF-A), known for its anti-angiogenic properties. The off-label use of bevacizumab has stirred legal, financial, industrial, and ethical complexities. With its potential to treat diverse ocular conditions, this commentary delves into the multifaceted dimensions of bevacizumab's off-label utilization, encompassing clinical trials, regulatory frameworks, safety considerations, comparative effectiveness, and economic implications.<br /> (Copyright © 2024 Copyright: © 2024 Indian Journal of Ophthalmology.)